Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Novacyt   /   Novacyt de volgende biotech raket!

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

Laatste koers (eur) Verschil Volume
0,618   0,000   (0,00%) Dagrange 0,618 - 0,645 193.230   Gem. (3M) 374,7K

Novacyt de volgende biotech raket!

Volgen
70.788 Posts
Pagina: «« 1 ... 1352 1353 1354 1355 1356 ... 3540 »» | Laatste | Omlaag ↓
  4. Johny 29 september 2020 08:05
    quote:

    Clarice schreef op 28 september 2020 22:37:

    29/08/19: mijn eerste aankoop van 15k stuks novacyt aan 0,08€. Bedoeling was om op lange termijn (> 10 jaar) iets aan over te houden.
    01/10/19: verdubbeling van mijn positie aan 0,068€. Ik dacht bij mezelf: Dat moet dan toch wel de bodem zijn.
    09/12/19: Tiens, die doen dat zo slecht niet: we kopen er 20k bij aan 0,15.
    14/02/20: Dit is waanzin: die springen hier gewoon boven de euro. Snel verzilveren. We doen er 30k af (laatste aankoop + wat extra; uiteindelijk eruit aan 1,09 euro) en dit is dan meteen de beste belegging ooit. De andere 20k laten we verder rijpen.
    Vandaag: waanzin. Het wordt moeilijk om op de handen te blijven zitten en niet op die verkoopknop te drukken. Ik heb niets meer te verliezen dus we gaan vol voor de midcap...

    Goed gedaan, je moet het durven.en ontdekken en wat geluk hebben .
  5. TheBiG 29 september 2020 08:05
    Novacyt S.A.



    ("Novacyt" or the "Company")



    New contract with UK DHSC for instrument platforms and COVID-19 testing kits



    Paris, France and Camberley, UK - 29 September 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces it has signed a new supply contract with the UK Department of Health and Social Care (DHSC) for its q16 and q32 Rapid-PCR instrument platforms, exsig® COVID-19 Direct kits and genesig® SARS-CoV-2 Winterplex kits.



    This is the second major contract awarded by the DHSC to Primerdesign, the Company's wholly owned molecular diagnostics division, during the COVID-19 pandemic and follows the ongoing contract announced on 27 April 2020 for the supply of its PCR COVID-19 test.



    Under the terms of the contract, which is in two phases, Primerdesign will supply its products to the DHSC for up to six months. Phase one has an initial fixed term of 14 weeks with the potential to extend supply by a further 10 weeks. This first phase of the contract will involve the immediate deployment of 300 PCR instruments, related kits and support services with a minimum value of £150 million for the first 14 weeks. Based on this initial period, a further £100 million of revenue could be expected for the subsequent 10 weeks, however volumes can be varied up or down subject to certain notice criteria given by the DHSC.



    The second phase of the contract, which is optional by the DHSC, allows for the provision of up to 700 additional PCR instruments, related kits and support services, as well as additional COVID-19 products from the Company's portfolio where required. Depending upon the uptake, phase two of the contract could generate considerably more sales than the first phase.



    The intended use of the contract is for Novacyt to support the urgent requirement for COVID-19 testing of patients in the NHS. In addition to the provision of products, the Company will also provide training and maintenance services for the q16 and q32 instrument platforms.



    Novacyt has the capacity to meet the demand of both phases of this new contract, as well as to continue to build its sales across international markets.
  10. Speculatie 29 september 2020 08:17
    quote:

    Speculatie schreef op 28 september 2020 22:39:

    “with the government set to confirm the Primerdesign contract soon” --> het contract voor de 300 machines.
    Nou de RNS is duidelijk: het is inclusief kits, services. Wat een NIEUWS!

    Ik had dit dus in mijn andere visioen na 4 flessen wijn, maar durf geen getal op de koers te zetten.
  11. [verwijderd] 29 september 2020 08:17
    Paris, France and Camberley, UK – 29 September 2020 – Novacyt, an international
    specialist in clinical diagnostics, announces that, further to the announcement on 27 July 2020,
    the Company has launched a CE-Mark approved serology (antibody) 96-well plate ELISA
    (enzyme-linked immunosorbent assay) test for the detection of IgG antibodies to SARS-CoV-2
    derived from plasma and serum samples.
    The test has been launched by Microgen Bioproducts Limited (Microgen), which is part of
    Novacyt’s protein diagnostics division Lab21. The new antibody test complements Novacyt’s
    existing COVID-19 product portfolio, in particular the Company’s polymerase chain reaction
    (PCR) test for COVID-19, to provide clinicians with the diagnostic tools to detect and differentiate
    between active and prior SARS-CoV-2 infections in patients.
    The new antibody test has been validated in a study where 1,673 patient samples (112 positive
    samples and 1,561 negative samples) were evaluated. The test demonstrated 100% sensitivity
    in patients that were tested at 14 days after testing positive for COVID-19 by a PCR test. The
    antibody test also demonstrated 99.4% specificity.
    The ELISA test has been designed for use in all established central laboratories and follows a
    standard ELISA protocol that makes it compatible with most 96-well plate automation systems.
    Novacyt has sufficient manufacturing capacity to deliver more than three million antibody tests
    per month initially and the Company is working with its manufacturing partner to ensure this
    can be increased depending on demand.
    Graham Mullis, Chief Executive Officer of Novacyt, commented:
    “Novacyt remains committed to supporting the global response to COVID-19 through the delivery
    of high performance diagnostics. We continue to strengthen our product offering in COVID-19
    testing as demand continues and we are delighted to launch an antibody test. We believe an
    antibody test plays an important role in aiding the diagnosis of COVID-19, as well as increasing
    our understanding of the disease through screening of populations for infection rates and
    immunity.”
  18. [verwijderd] 29 september 2020 08:25
    quote:

    TheBiG schreef op 29 september 2020 08:05:

    Novacyt S.A.



    ("Novacyt" or the "Company")



    New contract with UK DHSC for instrument platforms and COVID-19 testing kits



    Paris, France and Camberley, UK - 29 September 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces it has signed a new supply contract with the UK Department of Health and Social Care (DHSC) for its q16 and q32 Rapid-PCR instrument platforms, exsig® COVID-19 Direct kits and genesig® SARS-CoV-2 Winterplex kits.



    This is the second major contract awarded by the DHSC to Primerdesign, the Company's wholly owned molecular diagnostics division, during the COVID-19 pandemic and follows the ongoing contract announced on 27 April 2020 for the supply of its PCR COVID-19 test.



    Under the terms of the contract, which is in two phases, Primerdesign will supply its products to the DHSC for up to six months. Phase one has an initial fixed term of 14 weeks with the potential to extend supply by a further 10 weeks. This first phase of the contract will involve the immediate deployment of 300 PCR instruments, related kits and support services with a minimum value of £150 million for the first 14 weeks. Based on this initial period, a further £100 million of revenue could be expected for the subsequent 10 weeks, however volumes can be varied up or down subject to certain notice criteria given by the DHSC.



    The second phase of the contract, which is optional by the DHSC, allows for the provision of up to 700 additional PCR instruments, related kits and support services, as well as additional COVID-19 products from the Company's portfolio where required. Depending upon the uptake, phase two of the contract could generate considerably more sales than the first phase.



    The intended use of the contract is for Novacyt to support the urgent requirement for COVID-19 testing of patients in the NHS. In addition to the provision of products, the Company will also provide training and maintenance services for the q16 and q32 instrument platforms.



    Novacyt has the capacity to meet the demand of both phases of this new contract, as well as to continue to build its sales across international markets.
    AB!

    Nu weten we waarvoor die vacatures waren!
70.788 Posts
Pagina: «« 1 ... 1352 1353 1354 1355 1356 ... 3540 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee